Atea Pharmaceuticals (AVIR) said Wednesday that the first patient has been dosed in its late-stage trial comparing the combination regimen of bemnifosbuvir and ruzasvir with the combination regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus.
The bemnifosbuvir and ruzasvir regimen will be administered orally once a day for eight weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis, while the sofosbuvir and velpatasvir regimen will be administered orally once a day for 12 weeks, the company said.
The company said infection with chronic hepatitis C virus is the leading cause of liver cancer in the US, Europe and Japan.
Shares of Atea Pharmaceuticals were down more than 30% in recent premarket activity Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。